RadNet

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RadNet reports strong Q4 earnings, targets AI growth in 2023

RadNet's Q4 2022 performance demonstrated strong revenue and EBITDA growth, fueled by procedural demand and strategic investments in AI and expansion initiatives.
Despite challenges like labor market disruptions and a net loss, the company's focus on innovation, market positioning, and financial discipline bodes well for future profitability and growth.
Opportunities lie in AI revenue growth, de novo center profitability, and market expansion, positioning RadNet as a key player in the radiology industry with a clear path to sustained success.
With a commitment to quality services, shareholder value, and operational excellence, RadNet's strategic vision aligns with industry trends and growth opportunities, setting the stage for continued success and market leadership.

RadNet reports record Q1 revenue and EBITDA growth, eyes AI expansion

RadNet's Q1 2023 showcased strong financial performance and operational improvements. Despite challenges like net loss and labor inflation, the company is strategically positioned for growth through expansion and AI initiatives. Opportunities in advanced imaging services and cancer detection technologies present avenues for future success.

RadNet reports record Q2 earnings, eyes growth amid challenges

RadNet's Q2 2023 performance reflects strong revenue and EBITDA growth, driven by core Imaging Center segment.
While facing challenges like potential Medicare cuts and AI segment delays, the company is optimistic about growth opportunities.
Strategic initiatives in preventative medicine, AI, and outpatient services position RadNet for future success.
With a focus on innovation and financial strength, RadNet aims to capitalize on market shifts and technological advancements.

RadNet reports robust Q3 earnings, eyes growth through AI and partnerships

RadNet's Q3 performance reflects strong revenue growth and financial management, supported by AI division success and strategic initiatives for 2024.
Despite challenges such as staffing shortages and pricing discussions, the company's strengths in liquidity, debt management, and operational focus position it well for future growth.
Opportunities in acquisitions, AI investments, and partnerships offer avenues for expansion and innovation, driving RadNet's market leadership and service excellence.
Overall, RadNet's focus on growth, efficiency, and strategic partnerships underscores its commitment to sustainable success and market resilience in the healthcare industry.

RadNet reports record Q4 earnings, eyes AI growth opportunities

RadNet's Q4 2023 performance was strong, with record revenue and adjusted EBITDA driven by Imaging Center segment growth.
The company's focus on AI, acquisitions, and joint ventures presents growth opportunities but also challenges in reaching expansion targets.
Management's commitment to market leadership and financial strength positions RadNet well for future success and innovation.
RadNet's strategic investments and balance sheet strength support its growth initiatives and potential breakthroughs in AI solutions.

RadNet achieves record Q3 results, eyes AI growth opportunities

RadNet's Q3 2024 performance showcased exceptional financial results, underpinned by revenue growth, operational efficiency, and strategic guidance revisions for the full year.
The company's strengths lie in expansion initiatives, innovative collaborations, and a forward-looking approach towards technology commercialization and digital health advancement.
While facing challenges in regional adoption rates and program implementations, RadNet is well-positioned to capitalize on opportunities through strategic partnerships, AI profitability, and market expansion efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, March 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of $200,000,000 of shares of common stock. In addition, RadNet intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

RadNet Announces Proposed $200 Million Underwritten Public Offering of Common Stock

LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Gregory Sorensen, M.D., Chief Science Officer of RadNet and President of DeepHealth (RadNet's Artificial Intelligence Division) and Sham Sokka, Chief Operating & Technology Officer of RadNet's Digital Health, will be presenting at the Cowen & Company Healthcare Conference on Wednesday, March 6, 2024 at 2:10 p.m. Eastern Time.

RadNet, Inc. to Present at the 44th Annual Cowen & Company Healthcare Conference on Wednesday, March 6th

Does RadNet (RDNT) have what it takes to be a top stock pick for momentum investors? Let's find out.

RadNet (RDNT) Is Up 14.75% in One Week: What You Should Know

RadNet (RDNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RadNet (RDNT) Upgraded to Buy: What Does It Mean for the Stock?

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Raymond James 45th Annual Institutional Investors Conference in Orlando, Florida today, Monday, March 4, 2024 at 3:25 p.m. Eastern Time.

RadNet, Inc. to Present at the Raymond James 45th Annual Institutional Investors Conference Today, March 4th, 2024

RadNet, Inc. (RDNT) Q4 2023 Earnings Call Transcript

LOS ANGELES, Feb. 29, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 366 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter and full year ended December 31, 2023.

RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment

LOS ANGELES, Feb. 27, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a definitive agreement to purchase the assets of seven imaging centers in the greater Houston, Texas metropolitan area from Houston Medical Imaging, LLC. Upon closing the acquisition, which is anticipated to occur during the second quarter, 2024, RadNet will be entering its first new market since 2020. The acquisition is subject to customary closing conditions.

RadNet to Enter the Houston, Texas Market through Platform Acquisition of Houston Medical Imaging

LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces the formation of a new diagnostic imaging career training program created in partnership with JVS SoCal, a workforce development non-profit and social service agency. ImagingWorks® intends to address a growing need for qualified candidates for careers in diagnostic imaging through creating a comprehensive program for workforce education and training, which shall include internships and job placement upon graduation at RadNet or at other similar diagnostic imaging facilities.

RadNet and JVS SoCal Create ImagingWorks®, an Innovative Partnership to Launch Career Training Programs for Medical Imaging

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2023 financial results on Friday, March 1, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its Fourth Quarter 2023 Financial Results Conference Call

RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility.

RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation

LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that its joint ventured Arizona Diagnostic Radiology Group, LLC (“Arizona Diagnostic Radiology”) has acquired seven outpatient imaging centers in Phoenix Arizona from Evernorth Care Group.

RadNet's Arizona Diagnostic Radiology Group Joint Venture Acquires Seven Outpatient Imaging Centers in Phoenix, Arizona

LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer and Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 4:30 p.m. PST.

RadNet, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 10th, 2024

LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces MammogramNow, an innovative screening mammography service set to debut at the Walmart Supercenter in Milford, Delaware, on December 8th. This pioneering initiative aims to enhance breast health awareness and accessibility, including the integration of cutting-edge DeepHealth® (deephealth.com) technology, into the Walmart Supercenter environment, providing women with convenient access to crucial breast cancer screening services.

RadNet Launches a Pilot Inside Walmart of its New MammogramNow™ Offering

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces the launch of DeepHealth, a health informatics portfolio designed to dramatically drive efficiency and transform radiology's role in healthcare.

RadNet Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2023 Leveraged Finance Conference in Boca Raton, FL on Tuesday, November 28, 2023 at 11:10 a.m. Pacific Time (2:10 p.m. Eastern Time).

RadNet, Inc. to Present at the BofA Securities 2023 Leveraged Finance Conference on November 28, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Maverick Medical AI, or Maverick, a provider of an innovative and autonomous AI-powered medical coding platform, announced today that it has partnered with RadNet, Inc. (NASDAQ: RDNT), a leading national provider of free-standing, fixed-site radiology diagnostic imaging services in the United States. Through this partnership, Maverick integrates its Autonomous Medical Coding platform as the solution for RadNet's medical coding needs, which will help optimize i.

Maverick Medical AI Partners with RadNet to Launch AI-powered Medical Coding Across U.S. Imaging Sites

LOS ANGELES, Nov. 15, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2023 Conference on Thursday, November 16th at 1:00 p.m. Eastern Time.

RadNet, Inc. to Present at the Sidoti & Company Fall 2023 Virtual Conference on Thursday, November 16th

RadNet, Inc. (NASDAQ:RDNT ) Q3 2023 Earnings Conference Call November 9, 2023 10:30 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Howard Berger - Chairman, President & Chief Executive Officer Conference Call Participants Jack Slevin - Jefferies Nathan Malewicki - Raymond James Larry Solow - CJS Securities Jim Sidoti - Sidoti & Company Rishi Parekh - JPMorgan Ed Kressler - TPG Angelo Gordon Operator Good day and welcome to the RadNet Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

RadNet, Inc. (RDNT) Q3 2023 Earnings Call Transcript

RadNet (RDNT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago.

RadNet (RDNT) Q3 Earnings and Revenues Beat Estimates

LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 366 owned and operated outpatient imaging centers, today reported financial results for its third quarter of 2023.

RadNet Reports Third Quarter Financial Results and Revises Upwards 2023 Financial Guidance Range for Adjusted EBITDA

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy RadNet (RDNT) Stock?

LOS ANGELES, Oct. 17, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its third quarter 2023 financial results on Thursday, November 9th, 2023 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its Third Quarter 2023 Financial Results Conference Call

RadNet is capturing a strong demand for diagnostic imaging which benefits from several secular growth trends. The approval of new Alzheimer's drugs represents a growth driver given the requirement of an amyloid PET scan in the initial treatment assessment. We are bullish on the stock and see room for shares to climb higher.

RadNet Stock: Bullish With Several Growth Tailwinds For Diagnostic Imaging

Bioventus

Royal Philips

We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.

News for RadNet Stock (RDNT)